Skip to main content

Advertisement

Log in

Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know

  • Review
  • Published:
Journal of Nephrology Aims and scope Submit manuscript

Abstract

Tacrolimus has long been the cornerstone of the immunosuppressive standard-of-care in kidney transplantation. Until recently, only an immediate-release formulation of tacrolimus was available in the clinic for twice-daily administration, a schedule that is known to hamper prescription adherence and contributes to the already significant tacrolimus interactions with other drugs and meals. In order to improve patient compliance, two once-daily prolonged-release formulations of tacrolimus have recently been developed and approved. Here we will analyze the main characteristics of these two prolonged-release formulations with the aim to provide practical clinical information for a fully aware drug prescription. Finally, the theoretical advantages of the prolonged-release formulations in terms of prescription adherence, blood level steadiness and drug efficacy and tolerability will be critically reviewed, in order to define the profile of renal recipients who may benefit most from the switch to once-daily tacrolimus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1–S155. doi:10.1111/j.1600-6143.2009.02834.x

    Google Scholar 

  2. Ekberg H, Tedesco-Silva H, Demirbas A et al (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357(25):2562–2575

    Article  CAS  PubMed  Google Scholar 

  3. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC (2005) Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 331(7520):810

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hart A, Smith JM, Skeans MA et al (2016) OPTN/SRTR annual data report 2014. Am J Transplant 16(S2):11–46. doi:10.1111/ajt.13666 (Special Issue)

    Article  PubMed  Google Scholar 

  5. Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351(26):2715–2729

    Article  CAS  PubMed  Google Scholar 

  6. Provenzani A, Santeusanio A, Mathis E et al (2013) Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol 19(48):9156–9173. doi:10.3748/wjg.v19.i48.9156

    Article  PubMed  PubMed Central  Google Scholar 

  7. Grinyó JM, Petruzzelli S (2014) Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations. Expert Rev Clin Immunol. 10(12):1567–1579. doi:10.1586/1744666X.2014.983903

    Article  PubMed  Google Scholar 

  8. Garnock-Jones KP (2015) Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients. Drugs 75(3):309–320. doi:10.1007/s40265-015-0349-2

    Article  CAS  PubMed  Google Scholar 

  9. www.fda.gov/downloads/Drug/GuidanceComplianceRegulatoryInformation/Guidance/UCM181006.pdf. Accessed 16 Mar 2016

  10. Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43(10):623–653

    Article  CAS  PubMed  Google Scholar 

  11. Prograf (2013) Prescribing information. Astellas Pharma US, Inc; Northbrook

  12. Ekberg H, Bernasconi C, Tedesco-Silva H et al (2009) Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 9(8):1876–1885. doi:10.1111/j.1600-6143.2009.02726.x

    Article  CAS  PubMed  Google Scholar 

  13. Malvezzi P, Rostaing L (2015) The safety of calcineurin inhibitors for kidney-transplant patients. Expert Opin Drug Saf 14(10):1531–1546. doi:10.1517/14740338.2015.1083974

    Article  PubMed  Google Scholar 

  14. Cippà PE, Schiesser M, Ekberg H et al (2015) Risk stratification for rejection and infection after kidney transplantation. Clin J Am Soc Nephrol 10(12):2213–2220. doi:10.2215/CJN.01790215

    Article  PubMed  PubMed Central  Google Scholar 

  15. Vanhove T, Annaert P, Kuypers DR (2016) Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev 48(1):88–112. doi:10.3109/03602532.2016.1151037

    Article  CAS  PubMed  Google Scholar 

  16. Paine MF, Khalighi M, Fisher JM et al (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283(3):1552–1562

    CAS  PubMed  Google Scholar 

  17. Masuda S, Uemoto S, Goto M, Fujimoto Y, Tanaka K, Inui K (2004) Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Clin Pharmacol Ther 75(4):352–361

    Article  CAS  PubMed  Google Scholar 

  18. Christians U, Jacobsen W, Benet LZ, Lampen A (2002) Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41(11):813–851

    Article  CAS  PubMed  Google Scholar 

  19. Nowack R (2008) Herb-drug interactions in nephrology: documented and theoretical. Clin Nephrol 69(5):319–325

    Article  CAS  PubMed  Google Scholar 

  20. Bekersky I, Dressler D, Mekki QA (2001) Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol 41(2):176–182

    Article  CAS  PubMed  Google Scholar 

  21. Park SI, Felipe CR, Pinheiro-Machado PG, Garcia R, Tedesco-Silva H Jr, Medina-Pestana JO (2007) Circadian and time-dependent variability in tacrolimus pharmacokinetics. Fundam Clin Pharmacol 21(2):191–197

    Article  CAS  PubMed  Google Scholar 

  22. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000712/WC500022237.pdf. Accessed 16 Mar 2016

  23. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000712/WC500022234.pdf. Accessed 16 Mar 2016

  24. MeltDose® Technology by the US Patent and Trademark Office. US7217431

  25. Nigro V, Glicklich A, Weinberg J (2013) Improved bioavailability of MELTDOSE once-daily formulation of tacrolimus (LCP-Tacro) with controlled agglomeration allows for consistent absorption over 24 Hrs: a scintigraphic and pharmacokinetic evaluation. Am J Transplant. Poster, Abstract# B1034

  26. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002655/WC500170412.pdf. Accessed 16 Mar 2016

  27. Staatz CE, Tett SE (2015) Clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients. Clin Pharmacokinet 54(10):993–1025. doi:10.1007/s40262-015-0282-2

    Article  CAS  PubMed  Google Scholar 

  28. de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y (2010) Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 90(5):523–529. doi:10.1097/TP.0b013e3181e9feda

    Article  PubMed  Google Scholar 

  29. Wu MJ, Cheng CY, Chen CH et al (2011) Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. Transplantation 92(6):648–652. doi:10.1097/TP.0b013e3182292426

    Article  CAS  PubMed  Google Scholar 

  30. Hougardy JM, Broeders N, Kianda M et al (2011) Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 91(5):566–569. doi:10.1097/TP.0b013e3182098ff0

    Article  CAS  PubMed  Google Scholar 

  31. Gaber AO, Alloway RR, Bodziak K, Kaplan B, Bunnapradist S (2013) Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation 96(2):191–197. doi:10.1097/TP.0b013e3182962cc1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Alloway RR, Eckhoff DE, Washburn WK, Teperman LW (2014) Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients. Liver Transpl 20(5):564–575. doi:10.1002/lt.23844

    Article  PubMed  Google Scholar 

  33. Barraclough KA, Isbel NM, Johnson DW, Campbell SB, Staatz CE (2011) Once- versus twice-daily tacrolimus: are the formulations truly equivalent? Drugs 71(12):1561–1577. doi:10.2165/11593890-000000000-00000

    Article  CAS  PubMed  Google Scholar 

  34. Alloway RR, Mulgaonkar S, Ueda D, et al (2011) A phase 2b, open-label, multi-center, prospective, randomized study to compare the pharmacokinetics and safety of LCP-Tacro™ tablets once-a-day to Prograf® capsules twice-a-day in de novo kidney transplant patients. Am J Transplant. Poster, Abstratct #1106

  35. Niioka T, Satoh S, Kagaya H et al (2012) Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation 94(10):1013–1019. doi:10.1097/TP.0b013e31826bc400

    Article  CAS  PubMed  Google Scholar 

  36. Tsuchiya T, Ishida H, Tanabe T et al (2013) Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. Transplantation 96(2):198–204. doi:10.1097/TP.0b013e318296c9d5

    Article  CAS  PubMed  Google Scholar 

  37. Stifft F, Stolk LM, Undre N, van Hooff JP, Christiaans MH (2014) Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. Transplantation 97(7):775–780. doi:10.1097/01.TP.0000437561.31212.0e

    CAS  PubMed  Google Scholar 

  38. Hardinger KL, Hutcherson T, Preston D, Murillo D (2012) Influence of pill burden and drug cost on renal function after transplantation. Pharmacot 32(5):427–432. doi:10.1002/j.1875-9114.2012.01032.x

    Article  Google Scholar 

  39. Sellarés J, de Freitas DG, Mengel M et al (2012) Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 12(2):388–399. doi:10.1111/j.1600-6143.2011.03840.x

    Article  PubMed  Google Scholar 

  40. Tielen M, van Exel J, Laging M et al (2014) Attitudes to medication after kidney transplantation and their association with medication adherence and graft survival: a 2-year follow-up study. J Transplant. doi:10.1155/2014/675301

    PubMed  PubMed Central  Google Scholar 

  41. Shuker N, van Gelder T, Hesselink DA (2015) Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev 9(2):78–84. doi:10.1016/j.trre.2015.01.002

    Article  Google Scholar 

  42. Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. J Clin Ther 23(8):1296–1310

    Article  CAS  Google Scholar 

  43. Obi Y, Ichimaru N, Kato T et al (2013) A single daily dose enhances the adherence to immunosuppressive treatment in kidney transplant recipients: a cross-sectional study. Clin Exp Nephrol. 17(2):310–315. doi:10.1007/s10157-012-0713-4

    Article  CAS  PubMed  Google Scholar 

  44. Kuypers DR, Peeters PC, Sennesael JJ et al (2013) Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation 95(2):333–340. doi:10.1097/TP.0b013e3182725532

    Article  CAS  PubMed  Google Scholar 

  45. van Boekel GA, Kerkhofs CH, Hilbrands LB (2013) Treatment satisfaction in renal transplant patients taking tacrolimus once daily. Clin Ther 35(11):1821–1829. doi:10.1016/j.clinthera.2013.09.014

    Article  PubMed  Google Scholar 

  46. Singh N, Von Visger J, Zachariah M (2015) Extended release once a day tacrolimus. Curr Opin Organ Transplant. 20(6):657–662. doi:10.1097/MOT.0000000000000251

    Article  CAS  PubMed  Google Scholar 

  47. Butler JA, Peveler RC, Roderick P, Horne R, Mason JC (2004) Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation 77(5):786–789

    Article  PubMed  Google Scholar 

  48. Muduma G, Shaw J, Hart WM, Odeyemi A, Odeyemi I (2014) Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales. Pat Pre Adher 8:1537–1546. doi:10.2147/PPA.S69461

    Google Scholar 

  49. Hardinger KL, Park JM, Schnitzler MA, Koch MJ, Miller BW, Brennan DC (2004) Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. Am J Transplant 4(4):621–625

    Article  CAS  PubMed  Google Scholar 

  50. Alloway R, Steinberg S, Khalil K et al (2005) Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc. 37(2):867–870

    Article  CAS  PubMed  Google Scholar 

  51. van Hooff J, Van der Walt I, Kallmeyer J et al (2012) Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. Ther Drug Monit 34(1):46–52. doi:10.1097/FTD.0b013e318244a7fd

    Article  PubMed  Google Scholar 

  52. Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T (2010) High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 25(8):2757–2763. doi:10.1093/ndt/gfq096

    Article  CAS  PubMed  Google Scholar 

  53. Revollo J (2015) Update on the clinical utility of once-daily tacrolimus in the management of transplantation. Drug Des Dev Ther 9:2581–2583. doi:10.2147/DDDT.S84301

    Article  Google Scholar 

  54. Niioka T, Kagaya H, Miura M et al (2013) Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. Eur J Clin Pharmacol 69(9):1659–1665. doi:10.1007/s00228-013-1514-8

    Article  CAS  PubMed  Google Scholar 

  55. Posadas Salas MA, Srinivas TR (2014) Update on the clinical utility of once-daily tacrolimus in the management of transplantation. Drug Des Dev Ther 8:1183–1194. doi:10.2147/DDDT.S55458

    Article  Google Scholar 

  56. Silva HT Jr, Yang HC, Abouljoud M et al (2007) One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transpl 7(3):595–608

    Article  CAS  Google Scholar 

  57. Silva HT Jr, Yang HC, Meier-Kriesche HU et al (2014) Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation 97(6):636–641. doi:10.1097/01.TP.0000437669.93963.8E

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Krämer BK, Charpentier B, Bäckman L et al (2010) Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 10(12):2632–2643. doi:10.1111/j.1600-6143.2010.03256.x

    Article  PubMed  Google Scholar 

  59. Han DJ, Park JB, Kim YS et al (2012) A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen. Transpl Proc 44(1):115–117. doi:10.1016/j.transproceed.2011.12.070

    Article  CAS  Google Scholar 

  60. Albano L, Banas B, Klempnauer JL, Glyda M, Viklicky O, Kamar N (2013) OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation 96(10):897–903. doi:10.1097/TP.0b013e3182a203bd

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Bunnapradist S, Ciechanowski K, West-Thielke P et al (2013) Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transpl 13(3):760–769. doi:10.1111/ajt.12035

    Article  CAS  Google Scholar 

  62. Budde K, Bunnapradist S, Grinyó JM et al (2014) Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. Am J Transpl 14(12):2796–2806. doi:10.1111/ajt.12955

    Article  CAS  Google Scholar 

  63. Rostaing L, Bunnapradist S, Grinyó JM et al (2016) Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: two-year results of phase 3, double-blind, randomized trial. Am J Kidney Dis 67(4):648–659. doi:10.1053/j.ajkd.2015.10.024

    Article  CAS  PubMed  Google Scholar 

  64. Considine A, Tredger JM, Heneghan M et al (2015) Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts. Liver Transpl 21(1):29–37. doi:10.1002/lt.24022

    Article  PubMed  Google Scholar 

  65. Adam R, Karam V, Delvart V et al (2015) Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. Am J Transplant 15(5):1267–1282. doi:10.1111/ajt.13171

    Article  CAS  PubMed  Google Scholar 

  66. Uchida J, Kuwabara N, Machida Y et al (2012) Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism. Transpl Proc 44(1):128–133. doi:10.1016/j.transproceed.2011.11.005

    Article  CAS  Google Scholar 

  67. Uchida J, Iwai T, Kabei K et al (2014) Effects of conversion from a twice-daily tacrolimus to a once-daily tacrolimus on glucose metabolism in stable kidney transplant recipients. Transpl Proc 46(2):532–536. doi:10.1016/j.transproceed.2013.11.146

    Article  CAS  Google Scholar 

  68. Langone A, Steinberg SM, Gedaly R et al (2015) Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transplant 29(9):796–805. doi:10.1111/ctr.12581

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Giovanni Piotti.

Ethics declarations

Conflict of interest

Giovanni Piotti reports receiving consultant fees from Chiesi Farmaceutici SPA as medical research physician for the development of the medical product Envarsus. Elena Cremaschi declares that she has no conflict of interest. Umberto Maggiore is an Advisory Board or has received lecture fees from Teva, Sandoz, Chiesi, Astellas, Novartis.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Piotti, G., Cremaschi, E. & Maggiore, U. Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know. J Nephrol 30, 53–61 (2017). https://doi.org/10.1007/s40620-016-0316-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40620-016-0316-3

Keywords

Navigation